CVRx to Showcase Barostim at Canaccord Growth Conference
Event summary
- CVRx to present at Canaccord Genuity's 46th Annual Growth Conference on August 11, 2026.
- Live webcast available at ir.cvrx.com; archived version accessible post-event.
- Barostim remains the only FDA-approved neuromodulation device for heart failure patients.
- Device holds CE Mark approval in Europe for heart failure and resistant hypertension.
The big picture
CVRx's presentation comes amid growing interest in neuromodulation for cardiovascular diseases, with Barostim positioned as a potential disruptor in heart failure treatment. The company faces competition from traditional therapies and emerging technologies, making investor conferences critical venues for differentiating its value proposition.
What we're watching
- Commercialization Pace
- How CVRx will leverage conference exposure to accelerate Barostim adoption in U.S. and EU markets.
- Regulatory Advantage
- Whether FDA Breakthrough Device designation will sustain competitive differentiation.
- Investor Sentiment
- The impact of conference messaging on investor perception of CVRx's growth trajectory.